Core Viewpoint - iCAD, Inc. and Koios Medical have formed a strategic reseller partnership to create a comprehensive AI suite for breast cancer detection, integrating iCAD's ProFound AI® with Koios SmartUltrasound™ to enhance the diagnostic pathway for radiologists [1][3][4]. Company Overview - iCAD, Inc. is a global leader in AI-powered cancer detection solutions, particularly known for its ProFound Breast Health Suite, which provides AI-driven mammography analysis for breast cancer detection and risk evaluation [6]. - Koios Medical specializes in AI-driven ultrasound cancer diagnosis, with its SmartUltrasound platform designed to accurately detect and diagnose breast and thyroid cancers [4][5]. Partnership Details - The partnership aims to streamline the acquisition and implementation of AI solutions in breast imaging, responding to the growing demand from radiologists for integrated, efficient, and accurate diagnostic tools [3][4]. - The collaboration is positioned as a customer-driven initiative, reflecting the increasing adoption of advanced AI technologies in breast imaging facilities [3]. Technology and Innovation - Koios SmartUltrasound utilizes AI algorithms to improve the speed and accuracy of disease diagnosis, particularly relevant for women with dense breast tissue, who often require alternatives to traditional mammography [4][5]. - The integration of iCAD's ProFound AI with Koios SmartUltrasound is expected to enhance workflow efficiency and diagnostic accuracy, providing a more comprehensive approach to breast cancer screening [4]. Market Context - The partnership highlights the trend of increasing utilization of AI solutions in healthcare, particularly in the field of breast cancer detection, as healthcare providers seek to improve clinical outcomes and reduce unnecessary procedures [3][4].
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025